Meagan Anne Jacoby MD

PubMed

• 1 citations
  Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.
  Ramzi Abboud, Mark A Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao
  Blood. 2025-03-27
• 4 citations
  Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes.
  Jacqueline S Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong
  Blood. 2025-03-13
• Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
  Meagan A Jacoby, Eric D Duncavage, Ajay Khanna, Gue Su Chang, Sridhar Nonavinkere Srivatsan
  Leukemia. 2025-01-01

Journal Articles

• Exome Analysis of Treatment‐Related AML After APL Suggests Secondary Evolution  
  John S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology
• Virescent Tongue  
  Rizwan Romee, Meagan Jacoby, Annals of Hematology

Abstracts/Posters

• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na¥ve Patients with Higher-Risk Myelodysplastic Syndrome
  Meagan Jacoby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
  Meagan Jacoby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018